Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Gottfried von Keudell
Cost-Effectiveness Analysis of Consolidation With Brentuximab Vedotin for High-Risk Hodgkin Lymphoma After Autologous Stem Cell Transplantation
Cancer
Cancer Research
Oncology
Related publications
Brentuximab Vedotin Salvage Followed by Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in High Risk Relapsed Refractory Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Improving Outcomes After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma in the Brentuximab Vedotin Era
Bone Marrow Transplantation
Transplantation
Hematology
BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Real-World Effectiveness of Brentuximab Vedotin Versus Physicians’ Choice Chemotherapy in Patients With Relapsed/Refractory Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the United Kingdom and Germany
Leukemia and Lymphoma
Cancer Research
Oncology
Hematology
Brentuximab Vedotin Prior to Allogeneic Stem Cell Transplantation in Hodgkin Lymphoma: A Report From the EBMT Lymphoma Working Party
British Journal of Haematology
Hematology
Treatment Pathways and Resource Use Associated With Recurrent Hodgkin Lymphoma After Autologous Stem Cell Transplantation
Bone Marrow Transplantation
Transplantation
Hematology
A Cost-Effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Journal of Health Economics and Outcomes Research
The Aethera Trial: An Ongoing Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Pcn175 - Brentuximab Vedotin Compared With Standard Therapy for Patients With Advanced-Stage Hodgkin’s Lymphoma: A Cost-Effectiveness Analysis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
